surmount-1 trial tirzepatide obesity without diabetes weight loss Effect of in trial. (BMI: body mass index; CI: SURMOUNT 1 // Three-Year Obesty

Health Canada approved Mounjaro (Tirzepatide for diabetes) in late 2023

Over all a great experience

Remember that if you're taking oral medications with a narrow therapeutic index or oral contraceptives, tirzepatide's effect on gastric emptying may reduce their exposure, particularly after initiation or dose increases of tirzepatide

Review your weight trend, side effects, dosing history, and overall well-being at least once per month

Some people round to 40 units for convenience, but that changes the dose from 7.5 mg to 8 mg

Your healthcare provider will assess your individual circumstances, review your HbA1c levels and overall metabolic control, and create a personalised plan for safely discontinuing treatment whilst maintaining your health outcomes